# Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease

> **NCT04838860** · PHASE2 · TERMINATED · sponsor: **RECORDATI GROUP** · enrollment: 22 (actual)

## Conditions studied

- Idiopathic Multicentric Castleman's Disease

## Interventions

- **DRUG:** Siltuximab

## Key facts

- **NCT ID:** NCT04838860
- **Lead sponsor:** RECORDATI GROUP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-31
- **Primary completion:** 2021-04-01
- **Final completion:** 2021-04-01
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Internal Company Decision
- **Last updated:** 2021-04-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04838860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04838860, "Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04838860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*